Medistim ASA

As of June 30, 2026, Medistim ASA carries a market capitalization of 376.63M, placing it among publicly traded companies globally. Its enterprise value stands at 370.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medistim ASA's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Medistim ASA has 18.28M shares outstanding.

As of June 30, 2026, Medistim ASA trades at a trailing price-to-earnings ratio of 24.51. The price-to-sales ratio is 5.63, and the price-to-book ratio stands at 10.35.

As of June 30, 2026, Medistim ASA trades at an EV/EBITDA multiple of 18.43 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medistim ASA trades at an EV/FCF ratio of 26.35, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 370.84M versus a market cap of 376.63M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medistim ASA maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.46, indicating elevated leverage, while an interest coverage ratio of 571.29 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Medistim ASA posted a return on equity (ROE) of 39.56, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 36.04 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 28.95, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.06, useful for judging operating efficiency across full business cycles. The company generates approximately 423,578.03 in revenue per employee across its workforce of 157.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.89 indicates how many times Medistim ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Medistim ASA recorded 4.52M in income tax expense. That works out to an effective tax rate of 22.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 19.88M, leaving 15.36M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Medistim ASA's stock has gained approximately 31.71% over the past 52 weeks. The 50-day moving average sits at 24.25, while the 200-day moving average is 21.28.

Over the twelve months ended June 30, 2026, Medistim ASA generated 66.82M in revenue and converted that into 15.36M in net income, yielding earnings per share of 0.84. EBITDA reached 20.12M, while operating income came in at 19.36M.

As of June 30, 2026, Medistim ASA holds 8.86M in cash and equivalents against 3.08M in total debt, resulting in a net debt position of -8.86M. Total book value stands at 36.37M, with working capital of 23.41M providing operational flexibility.

Medistim ASA produced 14.04M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Medistim ASA posted a gross margin of 80.94, reflecting its pricing power and cost economics. The operating margin of 28.98 and net profit margin of 22.99 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Medistim ASA paid dividends of 1.24 per share. The dividend payout ratio of 147.62 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.19, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medistim ASA shareholders.